Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Jul;85(2):182–189. doi: 10.1054/bjoc.2001.1849

Genetic heterogeneity and clonal evolution in neuroblastoma

J Mora 1,2, N-K V Cheung 1, W L Gerald 2
PMCID: PMC2364052  PMID: 11461074

Abstract

Tumour heterogeneity and clonal evolution at the genetic level may explain the development of malignant or resistant disease during clinical progression of neuroblastoma (NB). In this report we use 1p allelic analysis and DNA ploidy to evaluate clonal heterogeneity and clonal selection in vivo. We studied a total of 69 tumours from 29 patients with NB. To evaluate tumour heterogeneity and clonal evolution in vivo we used a panel of polymorphic allelic markers mapping to chromosome 1. 33 tumours from 12 patients (group 1) were obtained from different sites during the same surgery or at sequential surgeries without intervening chemotherapy to evaluate genetic heterogeneity. Paired samples from 10 patients (group 2) were used to evaluate clonal selection before and after chemotherapy. In 6 cases paired tumours and derived cell lines were studied. Analysis of DNA ploidy changes by karyotype, FISH and flow cytometry was performed in 15 tumours from 6 multiply recurred local-regional (LR) NB patients. Allelotype study revealed that 66% (8/12) of group 1 samples were heterogeneous, with distinct allelic patterns in tumour samples separated by time or location. In group 2 allelic patterns were different in post-chemotherapy specimens in 60% (6/10). DNA ploidy analysis showed that pre-chemotherapy samples contained 2 distinct ploidy clones, one diploid and one triploid, whereas all post-chemotherapy tumor samples were 100% diploid. These findings suggest that NB exhibits a high degree of clonal heterogeneity and clonal evolution occurs during the course of therapy and clinical progression. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: heterogeneity, neuroblastoma, clonal evolution, DNA ploidy

Full Text

The Full Text of this article is available as a PDF (80.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambros I. M., Zellner A., Roald B., Amann G., Ladenstein R., Printz D., Gadner H., Ambros P. F. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med. 1996 Jun 6;334(23):1505–1511. doi: 10.1056/NEJM199606063342304. [DOI] [PubMed] [Google Scholar]
  2. Ambros P. F., Ambros I. M., Strehl S., Bauer S., Luegmayr A., Kovar H., Ladenstein R., Fink F. M., Horcher E., Printz G. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour? Eur J Cancer. 1995;31A(4):510–515. doi: 10.1016/0959-8049(95)00044-j. [DOI] [PubMed] [Google Scholar]
  3. Brodeur G. M., Hayes F. A., Green A. A., Casper J. T., Wasson J., Wallach S., Seeger R. C. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients. Cancer Res. 1987 Aug 15;47(16):4248–4253. [PubMed] [Google Scholar]
  4. Brodeur G. M. Molecular basis for heterogeneity in human neuroblastomas. Eur J Cancer. 1995;31A(4):505–510. doi: 10.1016/0959-8049(95)00040-p. [DOI] [PubMed] [Google Scholar]
  5. Brodeur G. M., Pritchard J., Berthold F., Carlsen N. L., Castel V., Castelberry R. P., De Bernardi B., Evans A. E., Favrot M., Hedborg F. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993 Aug;11(8):1466–1477. doi: 10.1200/JCO.1993.11.8.1466. [DOI] [PubMed] [Google Scholar]
  6. Cheung N. K., Kushner B. H., LaQuaglia M., Kramer K., Gollamudi S., Heller G., Gerald W., Yeh S., Finn R., Larson S. M. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001 Jan;36(1):227–230. doi: 10.1002/1096-911X(20010101)36:1<227::AID-MPO1055>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  7. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  8. Gotoh T., Sugihara H., Matsumura T., Katsura K., Takamatsu T., Sawada T. Human neuroblastoma demonstrating clonal evolution in vivo. Genes Chromosomes Cancer. 1998 May;22(1):42–49. doi: 10.1002/(sici)1098-2264(199805)22:1<42::aid-gcc6>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  9. Hedley D. W. Flow cytometry using paraffin-embedded tissue: five years on. Cytometry. 1989 May;10(3):229–241. doi: 10.1002/cyto.990100302. [DOI] [PubMed] [Google Scholar]
  10. Kushner B. H., LaQuaglia M. P., Bonilla M. A., Lindsley K., Rosenfield N., Yeh S., Eddy J., Gerald W. L., Heller G., Cheung N. K. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol. 1994 Dec;12(12):2607–2613. doi: 10.1200/JCO.1994.12.12.2607. [DOI] [PubMed] [Google Scholar]
  11. Larson A. A., Kern S., Curtiss S., Gordon R., Cavenee W. K., Hampton G. M. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res. 1997 Sep 15;57(18):4082–4090. [PubMed] [Google Scholar]
  12. Mao L., Lee D. J., Tockman M. S., Erozan Y. S., Askin F., Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9871–9875. doi: 10.1073/pnas.91.21.9871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Martinsson T., Sjöberg R. M., Hedborg F., Kogner P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res. 1995 Dec 1;55(23):5681–5686. [PubMed] [Google Scholar]
  14. Mora J., Cheung N. K., Chen L., Qin J., Gerald W. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer. 2001 Jan 15;91(2):435–442. [PubMed] [Google Scholar]
  15. Mora J., Cheung N. K., Kushner B. H., LaQuaglia M. P., Kramer K., Fazzari M., Heller G., Chen L., Gerald W. L. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn. 2000 Feb;2(1):37–46. doi: 10.1016/S1525-1578(10)60613-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Shimada H., Ambros I. M., Dehner L. P., Hata J., Joshi V. V., Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999 Jul 15;86(2):349–363. [PubMed] [Google Scholar]
  17. Shimada H., Chatten J., Newton W. A., Jr, Sachs N., Hamoudi A. B., Chiba T., Marsden H. B., Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984 Aug;73(2):405–416. doi: 10.1093/jnci/73.2.405. [DOI] [PubMed] [Google Scholar]
  18. Suzuki T., Mugishima H., Chin M., Takamura M., Shichino H., Nagata T., Harada K. Case of neuroblastoma with differing cytologic and molecular biologic features at primary and metastatic sites. J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):176–177. doi: 10.1097/00043426-199703000-00018. [DOI] [PubMed] [Google Scholar]
  19. Taylor S. R., Blatt J., Costantino J. P., Roederer M., Murphy R. F. Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. Cancer. 1988 Aug 15;62(4):749–754. doi: 10.1002/1097-0142(19880815)62:4<749::aid-cncr2820620418>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES